A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and
preliminary efficacy of SH1573 in subjects with advanced relapsed, refractory acute
myelogenous leukemia that harbor an IDH2 mutation.